These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 28857806)

  • 1. Reversing Dabigatran Anticoagulation with Prothrombin Complex Concentrate versus Idarucizumab as Part of Multimodal Hemostatic Intervention in an Animal Model of Polytrauma.
    Honickel M; Braunschweig T; Rossaint R; Stoppe C; Ten Cate H; Grottke O
    Anesthesiology; 2017 Nov; 127(5):852-861. PubMed ID: 28857806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of dabigatran anticoagulation ex vivo: Porcine study comparing prothrombin complex concentrates and idarucizumab.
    Honickel M; Treutler S; van Ryn J; Tillmann S; Rossaint R; Grottke O
    Thromb Haemost; 2015 Apr; 113(4):728-40. PubMed ID: 25567155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversing Rivaroxaban Anticoagulation as Part of a Multimodal Hemostatic Intervention in a Polytrauma Animal Model.
    Rayatdoost F; Braunschweig T; Maron B; Schöchl H; Akman N; Rossaint R; Herzog E; Heitmeier S; Grottke O
    Anesthesiology; 2021 Oct; 135(4):673-685. PubMed ID: 34370811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of combined idarucizumab and prothrombin complex concentrate treatment for bleeding related to dabigatran in a lethal porcine model of double trauma.
    Honickel M; Braunschweig T; Rossaint R; Schöchl H; Grottke O
    Transfusion; 2019 Apr; 59(4):1376-1387. PubMed ID: 30586470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapy with activated prothrombin complex concentrate is effective in reducing dabigatran-associated blood loss in a porcine polytrauma model.
    Honickel M; Maron B; van Ryn J; Braunschweig T; ten Cate H; Spronk HM; Rossaint R; Grottke O
    Thromb Haemost; 2016 Jan; 115(2):271-84. PubMed ID: 26333775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prothrombin Complex Concentrate Is Effective in Treating the Anticoagulant Effects of Dabigatran in a Porcine Polytrauma Model.
    Honickel M; Braunschweig T; van Ryn J; Ten Cate H; Spronk HM; Rossaint R; Grottke O
    Anesthesiology; 2015 Dec; 123(6):1350-61. PubMed ID: 26414500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of dabigatran by intraosseous or intravenous idarucizumab in a porcine polytrauma model.
    Akman N; Braunschweig T; Honickel M; Schütt K; Schöchl H; Stoppe C; Rossaint R; Grottke O
    Br J Anaesth; 2018 May; 120(5):978-987. PubMed ID: 29661415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dose requirements for idarucizumab reversal of dabigatran in a lethal porcine trauma model with continuous bleeding.
    Honickel M; Spronk HM; Rossaint R; Stoppe C; van Ryn J; Ten Cate H; Grottke O
    Thromb Haemost; 2017 Jun; 117(7):1370-1378. PubMed ID: 28424818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemostatic Therapy Using Tranexamic Acid and Coagulation Factor Concentrates in a Model of Traumatic Liver Injury.
    Zentai C; van der Meijden PE; Braunschweig T; Hueck N; Honickel M; Spronk HM; Rossaint R; Grottke O
    Anesth Analg; 2016 Jul; 123(1):38-48. PubMed ID: 27192476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversing the anticoagulation effects of dabigatran.
    Dager WE; Banares L
    Hosp Pract (1995); 2017 Apr; 45(2):29-38. PubMed ID: 28335637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.
    Glund S; Stangier J; Schmohl M; Gansser D; Norris S; van Ryn J; Lang B; Ramael S; Moschetti V; Gruenenfelder F; Reilly P; Kreuzer J
    Lancet; 2015 Aug; 386(9994):680-90. PubMed ID: 26088268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Idarucizumab, a Specific Dabigatran Reversal Agent, Reduces Blood Loss in a Porcine Model of Trauma With Dabigatran Anticoagulation.
    Grottke O; Honickel M; van Ryn J; ten Cate H; Rossaint R; Spronk HM
    J Am Coll Cardiol; 2015 Sep; 66(13):1518-9. PubMed ID: 26403349
    [No Abstract]   [Full Text] [Related]  

  • 13. Idarucizumab for Reversing Dabigatran-Induced Anticoagulation: A Systematic Review.
    Thibault N; Morrill AM; Willett KC
    Am J Ther; 2018; 25(3):e333-e338. PubMed ID: 27175894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study.
    Pollack CV; Bernstein R; Dubiel R; Reilly P; Gruenenfelder F; Huisman MV; Kam CW; Kleine E; Levy JH; Sellke FW; Steiner T; Ustyugova A; Weitz JI
    J Med Econ; 2017 May; 20(5):435-442. PubMed ID: 27981865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of prothrombin complex concentrates for the emergency reversal of dabigatran-induced anticoagulation.
    Grottke O; Aisenberg J; Bernstein R; Goldstein P; Huisman MV; Jamieson DG; Levy JH; Pollack CV; Spyropoulos AC; Steiner T; Del Zoppo GJ; Eikelboom J
    Crit Care; 2016 Apr; 20(1):115. PubMed ID: 27125504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of dabigatran after overdosage: two case reports and suggestions for monitoring.
    Billoir P; Girault C; Barbay V; Boyer D; Grangé S; Fresel M; Chrétien MH; Le Cam Duchez V
    Blood Coagul Fibrinolysis; 2018 Nov; 29(7):653-655. PubMed ID: 30045050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-Analysis of Reversal Agents for Severe Bleeding Associated With Direct Oral Anticoagulants.
    Gómez-Outes A; Alcubilla P; Calvo-Rojas G; Terleira-Fernández AI; Suárez-Gea ML; Lecumberri R; Vargas-Castrillón E
    J Am Coll Cardiol; 2021 Jun; 77(24):2987-3001. PubMed ID: 34140101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incomplete dabigatran reversal with idarucizumab.
    Steele AP; Lee JA; Dager WE
    Clin Toxicol (Phila); 2018 Mar; 56(3):216-218. PubMed ID: 28704111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment.
    Eikelboom JW; van Ryn J; Reilly P; Hylek EM; Elsaesser A; Glund S; Pollack CV; Weitz JI
    J Am Coll Cardiol; 2019 Oct; 74(14):1760-1768. PubMed ID: 31582135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Idarucizumab: First Global Approval.
    Burness CB
    Drugs; 2015 Dec; 75(18):2155-61. PubMed ID: 26578027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.